PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL

[1]  H. Dombret,et al.  Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups. , 2009 .

[2]  Carl W. Miller,et al.  Hidden Abnormalities and Novel Classification of t(15;17) APL Based on Genomic Alterations. , 2007 .

[3]  H. Dombret,et al.  Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. , 2008, Blood.

[4]  C. Sawyers,et al.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. , 2007, The Journal of clinical investigation.

[5]  C. Bloomfield,et al.  Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710. , 2006 .

[6]  H. Dombret,et al.  Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials) , 2006, Leukemia.

[7]  C. Willman,et al.  Relapse of acute promyelocytic leukemia with PML-RARα mutant subclones independent of proximate all-trans retinoic acid selection pressure , 2006, Leukemia.

[8]  H. Dombret,et al.  Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials). , 2005 .

[9]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[10]  V. Lallemand-Breitenbach,et al.  Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission , 2001, Oncogene.

[11]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.